• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.马来西亚国家心血管疾病数据库的见解:老年急性冠状动脉综合征患者的双联抗血小板治疗处方趋势及死亡率结果
J Geriatr Cardiol. 2025 Feb 28;22(2):237-245. doi: 10.26599/1671-5411.2025.02.004.
2
Trends of prescribing adherence of antiplatelet agents in Hong Kong patients with acute coronary syndrome: a 10-year retrospective observational cohort study.香港急性冠脉综合征患者抗血小板药物处方依从性的趋势:一项 10 年回顾性观察性队列研究。
BMJ Open. 2020 Dec 3;10(12):e042229. doi: 10.1136/bmjopen-2020-042229.
3
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.接受冠状动脉介入治疗后接受双联抗血小板治疗和三联治疗的患者的出血风险:ADAPTT 回顾性基于人群的队列研究。
Health Technol Assess. 2023 May;27(8):1-257. doi: 10.3310/MNJY9014.
4
Intervention and in-hospital pharmacoterapies in octogenarian with acute coronary syndrome: a 10-year retrospective analysis of the Malaysian National Cardiovascular Database (NCVD) registry.80 岁以上急性冠状动脉综合征患者的干预和院内药物治疗:马来西亚国家心血管数据库(NCVD)注册中心的 10 年回顾性分析。
BMC Geriatr. 2022 Jan 4;22(1):23. doi: 10.1186/s12877-021-02724-7.
5
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.接受普拉格雷或替格瑞洛治疗的急性冠脉综合征患者中长程与短程双联抗血小板治疗与冠状动脉血运重建:来自 RENAMI 注册研究的结果。
Eur J Prev Cardiol. 2020 May;27(7):696-705. doi: 10.1177/2047487319836327. Epub 2019 Mar 12.
6
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.在英国,接受经皮冠状动脉介入治疗 (PCI) 的急性冠状动脉综合征 (ACS) 患者的真实世界出血情况:一项基于人群的队列研究模拟“目标试验”。
Open Heart. 2022 Aug;9(2). doi: 10.1136/openhrt-2022-001999.
7
Trends in dual antiplatelet therapy regimens and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention with drug-eluting stents: A multicenter real-world study.接受药物洗脱支架经皮冠状动脉介入治疗的急性冠状动脉综合征患者双重抗血小板治疗方案及临床结局的趋势:一项多中心真实世界研究
Chronic Dis Transl Med. 2024 Nov 14;11(1):57-68. doi: 10.1002/cdt3.154. eCollection 2025 Mar.
8
Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).在英国,综合评估不同双联抗血小板治疗 (DAPT) 和三联治疗 (TT) 方案处方患者的出血情况:三个基于人群的队列研究的研究方案,模拟“目标试验”(ADAPTT 研究)。
BMJ Open. 2019 Jun 4;9(6):e029388. doi: 10.1136/bmjopen-2019-029388.
9
Proton pump inhibitor co-prescription with dual antiplatelet therapy among patients with acute coronary syndrome in Qatar.卡塔尔急性冠状动脉综合征患者中质子泵抑制剂与双重抗血小板治疗的联合处方情况。
Int J Clin Pharm. 2016 Apr;38(2):353-61. doi: 10.1007/s11096-016-0250-4. Epub 2016 Jan 9.
10
Determinants and Temporal Trends of Dual Antiplatelet Therapy After Mild Noncardioembolic Stroke.轻度非心源性卒后双联抗血小板治疗的决定因素及时间趋势。
Stroke. 2023 Oct;54(10):2552-2561. doi: 10.1161/STROKEAHA.123.043769. Epub 2023 Sep 7.

本文引用的文献

1
2023 ESC Guidelines for the management of acute coronary syndromes.2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
2
Risk Stratification for Bleeding in the Elderly with Acute Coronary Syndrome: Not So Simple.老年急性冠状动脉综合征患者出血风险分层:并非如此简单。
Thromb Haemost. 2018 Jun;118(6):949-952. doi: 10.1055/s-0038-1649519. Epub 2018 May 30.
3
Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.老年急性冠状动脉综合征患者行早期经皮血运重建术时,使用普拉格雷低剂量与氯吡格雷标准剂量的比较。
Circulation. 2018 Jun 5;137(23):2435-2445. doi: 10.1161/CIRCULATIONAHA.117.032180. Epub 2018 Feb 19.
4
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).2017年欧洲心脏病学会(ESC)ST段抬高型急性心肌梗死患者管理指南:欧洲心脏病学会(ESC)ST段抬高型急性心肌梗死患者管理工作组
Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.
5
Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.糖尿病患者与非糖尿病患者药物洗脱支架植入术后短期与长期双重抗血小板治疗:来自随机试验的个体参与者数据的系统评价和荟萃分析
BMJ. 2016 Nov 3;355:i5483. doi: 10.1136/bmj.i5483.
6
P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.真实世界中应用于非 ST 段抬高型急性冠脉综合征患者的 P2Y12 受体抑制剂:来自当代欧洲注册研究的使用、患者选择和结局。
Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):229-43. doi: 10.1093/ehjcvp/pvw005. Epub 2016 Mar 2.
7
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries.基于当代欧洲注册研究的 STEMI 患者中 P2Y12 受体抑制剂治疗的应用、患者选择和结局。
Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):152-67. doi: 10.1093/ehjcvp/pvw003. Epub 2016 Jan 27.
8
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.非ST段抬高型急性冠脉综合征患者接受经皮冠状动脉介入治疗时,糖尿病、血小板反应性及SYNTAX评分与1年临床结局的关系。
EuroIntervention. 2016 Jun 20;12(3):312-8. doi: 10.4244/EIJV12I3A51.
9
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).2015年欧洲心脏病学会(ESC)非持续性ST段抬高型急性冠脉综合征患者管理指南:欧洲心脏病学会(ESC)非持续性ST段抬高型急性冠脉综合征患者管理工作组
Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
10
Long-term use of ticagrelor in patients with prior myocardial infarction.既往心肌梗死患者中长期使用替格瑞洛。
N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857. Epub 2015 Mar 14.

马来西亚国家心血管疾病数据库的见解:老年急性冠状动脉综合征患者的双联抗血小板治疗处方趋势及死亡率结果

Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.

作者信息

Suki Siti Zaleha, Zuhdi Ahmad Syadi Mahmood, Yahya Abqariyah, Zaharan Nur Lisa

机构信息

Department of Pharmacology, Universiti Malaya, Kuala Lumpur, Malaysia.

Centre of Preclinical Science Studies (Pharmacology), Faculty of Dentistry, Universiti Teknologi MARA, Selangor, Malaysia.

出版信息

J Geriatr Cardiol. 2025 Feb 28;22(2):237-245. doi: 10.26599/1671-5411.2025.02.004.

DOI:10.26599/1671-5411.2025.02.004
PMID:40104834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11911155/
Abstract

OBJECTIVES

To examine 5-year trends and variations in dual antiplatelet therapy (DAPT) prescription among multiethnic Malaysian patients aged 60 years and older.

METHODS

Using the Malaysian National Cardiovascular Disease-Acute Coronary Syndrome (NCVD-ACS) registry, DAPT 5-year temporal trends prescribing patterns at discharge were examined. Multivariate logistic regression was used to calculate the adjusted odds ratio (aOR) of DAPT prescription. The 1-year all-cause mortality by Cox proportional hazard regression model (adjusted hazard ratio, aHR) using inverse proportional weighting covariates adjustment was performed to assess DAPT prognostic impacts.

RESULTS

Data of patients aged 60 years and older were extracted from 2013 to 2017 ( = 3718, mean age: 68 ± 6.74 years, men: 72%, and Malay ethnicity: 43%). The majority of patients were diagnosed with non-ST-segment elevation acute coronary syndrome (63%), predisposed hypertension (76%) and were overweight (74%), while only 35% of patients underwent percutaneous coronary intervention. Over the five years, there was a significant increasing trend in DAPT prescriptions ( < 0.001), with the aspirin-clopidogrel combination being the most common. Aspirin-ticagrelor prescriptions have also increased over the years. Variations in DAPT prescriptions were observed based on patient characteristics. Patients who underwent percutaneous coronary intervention were more likely to be prescribed DAPT in general (aOR = 2.53, 95% CI: 1.95-3.28, < 0.001) and aspirin-ticagrelor specifically (aOR = 7.76, 95% CI: 5.65-10.68, < 0.001). Patients with chronic lung disease (aOR = 0.62, 95% CI: 0.42-0.92, = 0.02) and a history of angina within two weeks (aOR = 0.69, 95% CI: 0.56-0.85, < 0.001) were approximately 30% less likely to be prescribed DAPT. Approximately 15% of 1-year all-cause mortality were reported. Older patients prescribed DAPT showed significantly higher survival rates than those who were not (aHR < 1.0, < 0.001). Aspirin-ticagrelor was associated with higher survival rates than aspirin-clopidogrel (aHR = 0.21, 95% CI: 0.11-0.40, < 0.001).

CONCLUSIONS

Despite the optimal prescription rate and variation of DAPT in the older Malaysian population, there is room for investigation and improvement in the prescription of newer DAPT combinations that have been suggested to improve patient survival.

摘要

目的

研究60岁及以上马来西亚多民族患者双联抗血小板治疗(DAPT)处方的5年趋势及差异。

方法

利用马来西亚国家心血管疾病-急性冠状动脉综合征(NCVD-ACS)登记处的数据,研究出院时DAPT的5年时间趋势和处方模式。采用多因素逻辑回归计算DAPT处方的调整优势比(aOR)。使用逆概率加权协变量调整的Cox比例风险回归模型进行1年全因死亡率分析,以评估DAPT的预后影响。

结果

提取了2013年至2017年60岁及以上患者的数据(n = 3718,平均年龄:68±6.74岁,男性:72%,马来族裔:43%)。大多数患者被诊断为非ST段抬高型急性冠状动脉综合征(63%),患有高血压(76%)且超重(74%),而仅35%的患者接受了经皮冠状动脉介入治疗。在这五年中,DAPT处方有显著增加趋势(P < 0.001),阿司匹林-氯吡格雷组合最为常见。多年来,阿司匹林-替格瑞洛处方也有所增加。根据患者特征观察到DAPT处方存在差异。一般而言,接受经皮冠状动脉介入治疗的患者更有可能被开具DAPT处方(aOR = 2.53,95%置信区间:1.95 - 3.28,P < 0.001),尤其是阿司匹林-替格瑞洛(aOR = 7.76,95%置信区间:5.65 - 10.68,P < 0.001)。患有慢性肺病的患者(aOR = 0.62,95%置信区间:0.42 - 0.92,P = 0.02)和两周内有心绞痛病史的患者(aOR = 0.69,95%置信区间:0.56 - 0.85,P < 0.001)开具DAPT处方的可能性约低30%。报告的1年全因死亡率约为15%。开具DAPT处方的老年患者生存率显著高于未开具的患者(aHR < 1.0,P < 0.001)。阿司匹林-替格瑞洛与比阿司匹林-氯吡格雷更高的生存率相关(aHR = 0.21,95%置信区间:0.11 - 0.40,P < 0.001)。

结论

尽管马来西亚老年人群中DAPT的处方率和差异情况较为理想,但对于已被建议可提高患者生存率的新型DAPT组合的处方,仍有研究和改进的空间。